Deep-Vein Thrombosis

In the ONCO-DVT trial, patients with cancer and isolated distal deep vein thrombosis had fewer thrombotic events at 1 year with 12-month vs. 3-month edoxaban therapy, a finding that could change clinical guidance, according to a speaker.

Anticoagulation and antiplatelet therapy can reduce risk for venous thromboembolism in COVID-19; however, research suggests these treatments may not influence risk for mortality, speakers reported.